News | January 15, 2026
BioNTech maps pivotal oncology milestones for 2026
BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
Sabitha highlighted the growing relevance of minimally invasive therapies in modern medicine
CHOMax integrates cell line development, process development, analytics, and GMP manufacturing under robust quality processes
Vanda strongly disputes the FDA’s reasoning
The Phase 1 study, a non-randomised, open-label, multicentre trial, is evaluating IKS014 in patients with locally advanced or metastatic solid tumours expressing HER2
The company plans to use the newly secured funding to expand the indications of its Grabody platform into high-unmet-need areas
Harbour BioMed brings advanced antibody discovery platforms to the table
Additional investments planned to expand the site’s capacity and capabilities to support growing manufacturing programs
This collaboration sets the stage for WuXi Biologics’ first integrated CRDMO center in the region
DBT and BIRAC have partnered with CEPI since 2019, for cooperation on vaccine development for diseases of epidemic potential
Subscribe To Our Newsletter & Stay Updated
